NCT02823171View on ClinicalTrials.gov

To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Healthy
Interventions
DRUG

Treatment A: 400 mg Pacritinib P3CT

400-mg oral dose of pacritinib P3CT (reference) formulation capsules

DRUG

Treatment B: 400 mg of pacritinib FMI

400-mg oral dose of pacritinib FMI (test) formulation capsules

Trial Locations (1)

47710

Covance Clinical Research Unit Inc., Evansville

Sponsors

Lead Sponsor

CTI BioPharma

Collaborators (1)

Covance
All Listed Sponsors
collaborator

Covance

INDUSTRY

lead

CTI BioPharma

INDUSTRY